UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 10.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,945 shares of the company’s stock after selling 26,817 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.78% of Krystal Biotech worth $40,947,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. purchased a new stake in Krystal Biotech in the second quarter valued at approximately $28,000. AlphaMark Advisors LLC acquired a new stake in shares of Krystal Biotech in the second quarter valued at approximately $353,000. Blue Trust Inc. grew its position in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Down 4.6 %

NASDAQ KRYS opened at $185.97 on Wednesday. The stock has a market capitalization of $5.35 billion, a price-to-earnings ratio of 105.07 and a beta of 0.80. The business’s 50 day moving average is $180.92 and its two-hundred day moving average is $184.26. Krystal Biotech, Inc. has a 12-month low of $100.98 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s revenue was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.67) earnings per share. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on KRYS. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $202.29.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).